Use of proton-pump inhibitor (PPI) therapy is associated with an increased risk of fragility fractures, data from a large, prospective cohort study reveal. PPI therapy is commonly used to manage stomach acid-related diseases. An association of PPI therapy and increased fracture risk has been reported in a number of retrospective studies; however, in many of these studies adjustment was only made for a limited number of risk factors for fracture. In addition, the magnitude of the fracture risk associated with use of PPIs was unclear, as various levels of increased fracture risk have been reported in different studies.
展开▼
